The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...

INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.

Is it working? Are your symptoms improving, staying the same, or getting worse? You may be asked to fill out a couple of ...

The mainstay of treatment for urticaria is oral antihistamines as ... If possible, it is best to avoid all antihistamines in pregnancy, although none has proven teratogenic. If one is used ...

Urticaria and angioedema are hives and the swelling that can accompany them. Learn about the triggers, including allergies and stress, and how to get relief. What Are Autoimmune Hives and What Causes ...

Urticaria affects 10% to 25% of the population at some point in their life (Henderson, Fleischer, & Feldman, 2000). It is characterized by short-lived swellings of the skin, mouth, and genitalia ...

Treatment options can effectively manage symptoms, allowing people with the condition to manage some water exposure and improve their quality of life. If you suspect you may have aquagenic urticaria, ...

to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment. The target ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...